New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
08:03 EDTSPNCSpectranetics price target raised to $30 from $24 at Stifel
Stifel increased its price target on Spectranetics after the company announced positive results from its EXCITE ISR clinical trial. The firm sees the results as a major milestone for Spectranetics and keeps a Buy rating on the shares.
News For SPNC From The Last 14 Days
Check below for free stories on SPNC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
11:49 EDTSPNCSpectranetics devices used with PTA clinically superior to PTA alone
The Spectranetics Corporation announced that Eric Dippel, MD, at Transcatheter Cardiovascular Therapeutics, TCT, the annual scientific symposium of the Cardiovascular Research Foundation, presented findings from the EXCITE ISR clinical trial proving Spectranetics' laser atherectomy devices, used with PTA, also known as balloon angioplasty, are clinically superior to PTA alone in both safety and efficacy
September 15, 2014
07:45 EDTSPNCCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use